Formulating for the Future of Transplant Patient Therapy

Transplant Support

Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs.

Veloxis Pharmaceuticals A/S is headquartered Copenhagen, DK and operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.

Veloxis is committed to patient access and financial support for kidney transplant patients. Learn more about our prescription cost savings programs, click here Go to


Feb 28, 2018
Annual report 2017 Investor Call

Webcast Webcast

Conference call at 4:00 pm CET

Please join the event conference 5-10 minutes prior to the start time

Confirmation Code:    2569802

Denmark:    +45 35 15 81 21

United Kingdom:    +44 (0)330 336 9411

United States:    +1 646-828-8193

Stock Information